(P 328) INNOVATING SARCOMA EDUCATION: EARLY OUTCOMES OF THE ITALIAN SOCIETY OF SURGICAL ONCOLOGY (SICO) SARCOMA SOCIAL MULTI-PLATFORM JOURNAL CLUB INITIATIVE

Author(s)

Laura Samà, MD (she/her/hers)

Surgical Oncologist
IRCCS Humanitas Research Hospital
Rozzano, Milan, Lombardia, Italy

Co-Author(s)

Chiara Pagnoni, MD

General Surgeon
Fondazione Policlinico Universitario Campus Bio-Medico
Rome, Lazio, Italy
SC

Sara Coppola, MD

European Institute of Oncology IRCCS
Milan, Lombardia, Italy
CA

Carlo Abatini, MD

Fondazione Policlinico Universitario A. Gemelli IRCCS
Rome, Lazio, Italy
SA

Salvatore Asero, MD

Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi Catania
Catania, Sicilia, Italy
Marco Baia, MD (he/him/his)

Attending surgeon
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardia, Italy
FC

Ferdinando Carlo Maria Cananzi, MD (he/him/his)

Professor
Humanitas University
Rozzano, Milan, Lombardia, Italy
FC

Francesco Corona, MD

IRCCS Regina Elena National Cancer Institute
Rome, Lazio, Italy
FD

Franco De Cian, MD

IRCCS Ospedale Policlinico San Martino
Genoa, Liguria, Italy
MD

Massimiliano Di Marzo, MD

Istituto Nazionale Tumori-IRCCS-Fondazione "G. Pascale"
Naples, Campania, Italy
Marco Fiore, MD, FACS, FEBS

Surgeon
Fondazione IRCCS Istituto Nazionale dei Tumori
Milano, Lombardia, Italy
AL

Andrea Lauretta, MD

Centro di Riferimento Oncologico di Aviano (CRO), IRCCS
Aviano (PN), Friuli-Venezia Giulia, Italy
MM

Matteo Mascherini, MD

IRCCS Ospedale Policlinico San Martino
Genoa, Liguria, Italy
EP

Elisabetta Pennacchioli, MD

European Institute of Oncology, IRCCS
Milan, Lombardia, Italy
MR

Marco Rastrelli, MD

Veneto Institute of Oncology IOV-IRCCS
Padova, Veneto, Italy
SS

Sergio Sandrucci, MD

University of Turin
Torino, Piemonte, Italy
DS

Dimitrios Siatis, MD

Candiolo Cancer Institute, FPO – IRCCS
Torino, Piemonte, Italy
SV

Sergio Valeri, MD

Surgical Oncologist
Fondazione Policlinico Universitario Campus Bio-Medico
Rome, Lazio, Italy

Objective: In 2025, the Sarcoma Oncoteam of the Italian Society of Surgical Oncology (SICO) launched “SICO Sarcoma Social”, a social media-based journal club aimed at enhancing education on sarcoma through monthly, evidence-based posts. This report summarizes the first three months of activity in terms of content, engagement, and audience reach.

Methods: Launched in March 2025, the initiative runs across Instagram, X, and LinkedIn. Each monthly cycle includes a clinical case, a key reference, an expert-led video, and a Q&A post. Content is curated by SICO sarcoma surgeons and researchers using concise formats including surgical images, videos, and commentary. Metrics collected included views, shares, comments, and follower growth.

Results: From March to May 2025, 12 educational posts were published across three thematic series: right-sided retroperitoneal sarcoma, left-sided approaches, and neoadjuvant treatments. Instagram was the most impactful platform, with >300% follower growth, 25,000+ total views, and nearly 7,200 unique accounts reached. The top reel exceeded 8,700 views. Median post views were 1,291 (range 203–8,714). The audience was mostly aged 25–34 (54.5%) and 60.8% female. Most were based in Italy (61.8%), followed by the USA (10.3%) and India (5.6%); Milan alone represented 28%, followed by Rome (4.3%).

On LinkedIn, the page grew to over 200 followers, mostly senior professionals (46.8%) and fewer trainees (6.4%). Median impressions per post were 393 (range 36–1,229). The audience was again largely Italian (Milan 38.4%, Rome, Palermo, Catania), with international views from Europe (18%, notably Spain and the UK), Asia (7%), the Americas (4%), and Africa/Middle East (3%).

X fostered professional engagement, especially with senior international surgeons and academic societies, often driven by congress-related content.

Conclusion: SICO Sarcoma Social demonstrates how structured, evidence-based content can drive engagement and international collaboration in rare cancer education through social media platforms.